OXI-4503 DIPOTASSIUM

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H20O12P2.2K
Molecular Weight	568.4883
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[K+].[K+].COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C(OP(O)([O-])=O)=C1OP(O)([O-])=O

InChI

InChIKey=IQYUGENRXZHYER-XNOMRPDFSA-L

InChI=1S/C18H22O12P2.2K/c1-25-13-8-7-12(16(29-31(19,20)21)18(13)30-32(22,23)24)6-5-11-9-14(26-2)17(28-4)15(10-11)27-3;;/h5-10H,1-4H3,(H2,19,20,21)(H2,22,23,24);;/q;2*+1/p-2/b6-5-;;

HIDE SMILES / InChI

Molecular Formula	C18H20O12P2
Molecular Weight	490.2917
Charge	-2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Molecular Formula	K
Molecular Weight	39.0983
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://investor.mateon.com/news-releases/news-release-details/oxigene-announces-oxi4503-granted-orphan-designation-treatment | https://clinicaltrials.gov/ct2/show/NCT02576301 | https://clinicaltrials.gov/ct2/show/NCT00977210 | https://adisinsight.springer.com/drugs/800016894 | https://www.ncbi.nlm.nih.gov/pubmed/21276042

Oxi0-4503 (now known as combretastatin A1 phosphate), a diphosphate prodrug of combretastatin A1, was developed by Mateon therapeutics as a second-generation, dual-mechanism vascular disrupting agent from the combretastatin family. On November 21, 2012, Oxi-4503 has been granted orphan designation by the US Food and Drug Administration for the treatment of acute myelogenous leukemia. It is known that the orphan drug designation qualifies a company for several benefits, including the potential for market exclusivity, development grants, and tax credits. Oxi0-4503 is currently participating in phase I/II clinical trial the treatment of patients with acute myelogenous leukemia or myelodysplastic syndrome. In addition, phase I clinical trial was successfully completed where was studied the safety of Oxi0-4503 in patients with advanced solid tumors.

Approval Year

PubMed

Title	Date	PubMed
Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.	2006 Jul 1	16818709
Effect of vascular targeting agent Oxi4503 on tumor cell kinetics in a mouse model of colorectal liver metastasis.	2007 Jul-Aug	17695520
Alterations in vascular architecture and permeability following OXi4503 treatment.	2008 Jan	18043126

Sample Use Guides

In Vivo Use Guide

Solid Tumors: OXi4503 will be administered weekly for 3 weeks followed by a week with no treatment. The starting dose will be 0.06 mg/m2 given as an intravenous infusion over 10 minutes

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Fri Dec 15 19:41:32 GMT 2023` Edited by `admin` on `Fri Dec 15 19:41:32 GMT 2023`
Record UNII	Q9F7QEH36F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXI-4503 DIPOTASSIUM

Common Name

English

1,2-BENZENEDIOL, 3-METHOXY-6-((1Z)-2-(3,4,5-TRIMETHOXYPHENYL)ETHENYL)-, 1,2-BIS(DIHYDROGEN PHOSPHATE), POTASSIUM SALT (1:2)

Common Name

English

COMBRETASTATIN A-1 BIS(PHOSPHATE) DIPOTASSIUM SALT

Common Name

English

OXI-4503 DIPOTASSIUM SALT

Common Name

English

Code System Code Type Description

CAS

1014615-46-3

Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023

PRIMARY

PUBCHEM

46209855

Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023

PRIMARY

DRUG BANK

DBSALT001872

Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023

PRIMARY

FDA UNII

Q9F7QEH36F

Created by admin on Fri Dec 15 19:41:32 GMT 2023 , Edited by admin on Fri Dec 15 19:41:32 GMT 2023

PRIMARY

Related Record Type Details


					JH6Z94GLUD

Combretastatin A-1 phosphate

PARENT -> SALT/SOLVATE